Visual and refractive outcomes of small incision lenticule extraction for the correction of myopia: 1-year follow-up.
Visual and refractive outcomes of small incision lenticule extraction for the correction of myopia: 1-year follow-up.
复制标题
DOI：
10.1136/bmjopen-2015-008268
复制
发表时间：
2015-11-26
期刊：
影响因子：
2.9
通讯作者：
Kobashi H
中科院分区：
文献类型：
--
作者：
Kamiya K;Shimizu K;Igarashi A;Kobashi H
目的评价500 kHz飞秒激光小切口晶状体摘除（SMILE）治疗近视散光1年的临床效果。这项前瞻性研究评估了39例连续患者的52只眼睛（31.8±6.9岁，平均年龄±SD），球面等效度为- 4.11±1.73 D（范围为- 1.25至- 8.25 D），这些患者接受SMILE治疗近视和近视散光。术前、术后1周、术后1、3、6和12个月，我们评估了手术的安全性、有效性、可预测性、稳定性、角膜内皮细胞损失和不良事件。术后1年最小分辨角（logMAR）未矫正距离视力和矫正距离视力的对数分别为- 0.16±0.11和- 0.22±0.07。1年时，所有的眼睛都在目标矫正的±0.5 D范围内。术后1周至1年的明显屈光变化为- 0.05±0.32 D （p=0.20， Wilcoxon sign -rank检验）。内皮细胞密度由术前的2804±267个细胞/mm2降至术后1年的2743±308个细胞/mm2，差异无统计学意义（p=0.12）。观察期间无视力威胁并发症发生。SMILE矫正近视和近视散光的效果良好，1年随访期间内皮细胞密度未发生明显变化，未发生其他严重并发症，提示SMILE作为治疗此类眼睛的手术选择是可行的。
To assess the 1 year clinical outcomes of small incision lenticule extraction (SMILE) for the correction of myopia and myopic astigmatism using a 500 kHz femtosecond laser system. This prospective study evaluated 52 eyes of 39 consecutive patients (31.8±6.9 years, mean age±SD) with spherical equivalents of −4.11±1.73 D (range, −1.25 to −8.25 D) who underwent SMILE for myopia and myopic astigmatism. Preoperatively, 1 week, and 1, 3, 6 and 12 months postoperatively, we assessed the safety, efficacy, predictability, stability, corneal endothelial cell loss and the adverse events of the surgery. The logarithm of the minimal angle of resolution (logMAR) uncorrected distance visual acuity and LogMAR corrected distance visual acuity were −0.16±0.11 and −0.22±0.07, respectively, 1 year postoperatively. At 1 year, all eyes were within±0.5 D of the targeted correction. Manifest refraction changes of −0.05±0.32 D occurred from 1 week to 1 year postoperatively (p=0.20, Wilcoxon signed-rank test). The endothelial cell density was not significantly changed from 2804±267 cells/mm2 preoperatively to 2743±308 cells/mm2 1 year postoperatively (p=0.12). No vision-threatening complications occurred during the observation period. SMILE performed well in the correction of myopia and myopic astigmatism, and no significant change in endothelial cell density or any other serious complications occurred throughout the 1-year follow-up period, suggesting its viability as a surgical option for the treatment of such eyes.